双鹭药业
(002038)
| 流通市值：58.07亿 | | | 总市值：70.07亿 |
| 流通股本：8.52亿 | | | 总股本：10.27亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 433,638,552 | 670,983,014.82 | 643,139,595.37 | 683,831,097.67 |
| 应收票据及应收账款 | 114,670,019.55 | 154,045,649.68 | 197,439,901.29 | 200,470,744.96 |
| 应收账款 | 114,670,019.55 | 154,045,649.68 | 197,439,901.29 | 200,470,744.96 |
| 应收款项融资 | 771,658.01 | 852,673.01 | 1,799,649.6 | 98,648.4 |
| 预付款项 | 114,175,239.49 | 118,677,031.3 | 221,541,714.22 | 121,023,441.52 |
| 其他应收款合计 | 22,216,856.37 | 15,539,804.73 | 29,875,056.03 | 35,251,823.85 |
| 应收股利 | - | - | - | 14,700,000.01 |
| 存货 | 236,842,314.19 | 178,060,203.85 | 171,098,630.81 | 144,456,874.27 |
| 一年内到期的非流动资产 | - | - | 55,234,375 | 54,765,625.02 |
| 其他流动资产 | 794,860,395.27 | 786,261,927.44 | 790,682,490.51 | 791,520,862.94 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,204,724,372.87 | 2,415,088,082.81 | 2,675,312,708.26 | 2,639,981,026.24 |
| 非流动资产: | | | | |
| 长期股权投资 | 953,926,287.88 | 913,622,554.54 | 911,366,506.82 | 905,919,506.61 |
| 其他非流动金融资产 | 275,764,986.92 | 275,813,045.72 | 276,425,824.7 | 276,414,861.26 |
| 投资性房地产 | 13,402,837.89 | 13,629,269.64 | 13,855,701.39 | 14,082,133.14 |
| 固定资产 | 422,275,232.36 | 427,271,815.75 | 437,013,954.67 | 446,361,091.84 |
| 在建工程 | 83,292,668.13 | 65,443,390.34 | 60,189,386.97 | 56,974,742.72 |
| 无形资产 | 642,984,295.95 | 670,587,642.94 | 657,542,270.43 | 693,772,760.63 |
| 开发支出 | 496,091,641.11 | 480,602,440.28 | 477,609,874.64 | 449,896,301.73 |
| 长期待摊费用 | 1,858,170.98 | 1,858,170.98 | 1,997,641.06 | 1,997,641.06 |
| 其他非流动资产 | 817,312,944.18 | 827,297,231.22 | 800,646,130.83 | 792,361,780.21 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,706,909,065.4 | 3,676,125,561.41 | 3,636,647,291.51 | 3,637,780,819.2 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,911,633,438.27 | 6,091,213,644.22 | 6,311,959,999.77 | 6,277,761,845.44 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 98,871,063.9 | 86,323,583.58 | 258,497,412.51 | 250,755,038.49 |
| 其中：应付票据 | 1,260,000 | - | 37,593,280 | 37,593,280 |
| 应付账款 | 97,611,063.9 | 86,323,583.58 | 220,904,132.51 | 213,161,758.49 |
| 预收款项 | 15,987,770.68 | 108,000 | 1,360,701.82 | 485,450 |
| 合同负债 | 11,853,735.2 | 14,225,584.53 | 9,701,484.78 | 14,807,217.19 |
| 应付职工薪酬 | 32,569,394.75 | 31,449,018.97 | 34,710,210.91 | 38,919,326.35 |
| 应交税费 | 3,981,896.14 | 8,703,196.5 | 845,057.63 | 8,153,866.22 |
| 其他应付款合计 | 39,137,945.58 | 36,566,404.1 | 43,051,325.42 | 59,192,263.59 |
| 其他流动负债 | 2,157,419.51 | 1,097,514.54 | 745,748.03 | 1,013,110.45 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 204,559,225.76 | 178,473,302.22 | 348,911,941.1 | 373,326,272.29 |
| 非流动负债: | | | | |
| 递延收益 | 44,170,123.1 | 44,165,123.1 | 44,165,123.1 | 47,041,076.17 |
| 递延所得税负债 | 24,714,961.3 | 29,753,564.55 | 39,169,626.72 | 47,356,994.62 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 68,885,084.4 | 73,918,687.65 | 83,334,749.82 | 94,398,070.79 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 273,444,310.16 | 252,391,989.87 | 432,246,690.92 | 467,724,343.08 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 |
| 资本公积 | 49,615,655.87 | 49,615,655.87 | 49,615,655.87 | 49,615,655.87 |
| 其他综合收益 | 13,474,826.25 | 13,474,826.25 | 13,474,826.25 | 13,474,826.25 |
| 盈余公积 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 |
| 未分配利润 | 3,906,927,106.17 | 4,107,355,188.61 | 4,147,899,805.36 | 4,077,765,187.3 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 5,629,778,019.03 | 5,830,206,101.47 | 5,870,750,718.22 | 5,800,616,100.16 |
| 少数股东权益 | 8,411,109.08 | 8,615,552.88 | 8,962,590.63 | 9,421,402.2 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 5,638,189,128.11 | 5,838,821,654.35 | 5,879,713,308.85 | 5,810,037,502.36 |
| 负债和股东权益合计 | 5,911,633,438.27 | 6,091,213,644.22 | 6,311,959,999.77 | 6,277,761,845.44 |
| 公告日期 | 2024-10-26 | 2024-08-26 | 2024-04-24 | 2024-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |